Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei.

ABSTRACT:

Purpose

Pseudomyxoma peritonei (PMP) is a rare and poorly understood malignant condition characterized by the accumulation of intra-abdominal mucin produced from peritoneal metastases. Currently, cytoreductive surgery remains the mainstay of treatment but disease recurrence and death after relapse frequently occur in patients with PMP. New therapeutic strategies are therefore urgently needed for these patients.

Experimental design

A total of 120 PMP samples from 50 patients were processed to generate a collection of 50 patient-derived organoid (PDO) and xenograft (PDX) models. Whole exome sequencing, immunohistochemistry analyses, and in vitro and in vivo drug efficacy studies were performed.

Results

In this study, we have generated a collection of PMP preclinical mod

SUBMITTER: Martinez-Quintanilla J 

PROVIDER: S-EPMC11393541 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature